To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
NIH to License Odyssey Thera for Molecular Libraries Roadmap Initiative
Read time: Less than a minute
Odyssey Thera, Inc. has announced the signing of an agreement with the National Institutes of Health (NIH) to advance the goals of the Molecular Libraries Roadmap Initiative.
Under the agreement, Odyssey Thera will provide the NIH Chemical Genomics Center (NCGC) with access to proprietary human cell lines with state-of-the-art technology for screening biochemical pathways in living cells.
The technology, known as PCA (protein-fragment complementation assays), provides fluorescence sensors of bio-molecular interactions inside human cells.
Since these interactions comprise the pathways that regulate human health and disease processes, the assays enable screening for small molecules with direct relevance for pharmaceutical discovery.
The NCGC will use high-tech systems to screen its repository of over 100,000 chemically diverse small molecules against these pathways.
"Odyssey's technology provides a completely novel strategy for probing targets and pathways inside human cells," said Jim Inglese, Ph.D., Deputy Director of the NCGC.
He adds, "This strategy complements the advances made by the NIH Chemical Genomics Center, and could result in the identification of novel probes and new therapeutic strategies."
"This agreement reflects our commitment to dramatically accelerate and improve the process of drug discovery," said Marnie L. MacDonald, Ph.D., President and CEO of Odyssey Thera.
He adds, "The NCGC is leading the way in chemical biology approaches that will facilitate the discovery of new and better targets and drugs."
Under the agreement, Odyssey Thera will provide the NIH Chemical Genomics Center (NCGC) with access to proprietary human cell lines with state-of-the-art technology for screening biochemical pathways in living cells.
The technology, known as PCA (protein-fragment complementation assays), provides fluorescence sensors of bio-molecular interactions inside human cells.
Since these interactions comprise the pathways that regulate human health and disease processes, the assays enable screening for small molecules with direct relevance for pharmaceutical discovery.
The NCGC will use high-tech systems to screen its repository of over 100,000 chemically diverse small molecules against these pathways.
"Odyssey's technology provides a completely novel strategy for probing targets and pathways inside human cells," said Jim Inglese, Ph.D., Deputy Director of the NCGC.
He adds, "This strategy complements the advances made by the NIH Chemical Genomics Center, and could result in the identification of novel probes and new therapeutic strategies."
"This agreement reflects our commitment to dramatically accelerate and improve the process of drug discovery," said Marnie L. MacDonald, Ph.D., President and CEO of Odyssey Thera.
He adds, "The NCGC is leading the way in chemical biology approaches that will facilitate the discovery of new and better targets and drugs."
